Perfil clínico de lactentes portadores de anemia falciforme diagnosticados pelo programa de triagem neonatal – Etapa anterior à introdução de hidroxiuréia

Abstract

Backround: Sickle cell anemia is a genetic disease associated with substancial morbidity and mortality due to acute complications and organic disfunctions beggining in the first year of life. It can be diagnosed with the newborn trial tests. The early treatment with folic acid, painkillers and oral penicilin until five years of age contribute to a better life quality of those pacients. Hydroxycarbamide is a drug capable of reducing substancial the quantity and magnitude of complications related to the disease. Methods: The actual study was conducted with 28 children diagnosed with sicke cell anemia from the blood smear between october 2010 and october 2011. It was analised the clinical aspects related to the disease before the introduction of the hydroxcarbamide in the treatment of those pacients. Results: Every children use their medication every day. The disease may vary among them, because some of them already had acute complications of the disease. Discussion: Sickle cell anemia patients typically don’t have symptoms until six months of age because of the protection of the fetal haemoglobin. From this age on, they can have complications of the disease. These vary due to genetic and enviromental factors. The regular use of folic acid, oral penicilin and the immunization from Haemophilus and Pneumococcus can contribute to less complications related to the disease. Those are made in the routine of every pediatric hematology center. Conclusion: The studied children presented few symptoms and low complication taxes related to the disease.